Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P McGovern

Showing results (321-330 of 376) with videos related to

Pageof 38
Sort By:
The Lancet. Primary Care|May 11, 2026
Kidney outcomes with GLP-1 receptor agonists in people with type 2 diabetes already receiving SGLT2 inhibitors: a target trial emulation study using UK primary care dataThijs T Jansz, Andrew P McGovern, Katherine G Young, et al.
The American Journal of Sports Medicine|September 30, 2022
Relationship of Average Outcomes Scores and Change in Status Requires Further Interpretation Between 1 and 2 Years Following Hip ArthroscopyRyan P McGovern, RobRoy L Martin, John J Christoforetti, et al.
Diabetes, Obesity & Metabolism|June 4, 2026
Trends in Second-Line Initiations and Treatment Outcomes Across Age and Frailty Groups in People With Type 2 Diabetes: UK Population-Based Study, 2019-2024M M Dinsdale, K G Young, P Cardoso, et al.
Lancet (London, England)|February 28, 2025
A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation studyJohn M Dennis, Katherine G Young, Pedro Cardoso, et al.
Diabetes Care|May 20, 2026
Precision Prescribing of SGLT2 Inhibitors in Individuals With Type 2 Diabetes for Primary Prevention of Heart Failure: Model Development and Validation StudyKatherine G Young, Andrew P McGovern, Rhian Hopkins, et al.
Medrxiv : the Preprint Server for Health Sciences|May 3, 2023
Precision medicine in type 2 diabetes: A systematic review of treatment effect heterogeneity for GLP1-receptor agonists and SGLT2-inhibitorsKatherine G Young, Eram Haider McInnes, Robert J Massey, et al.
The Lancet. Digital Health|November 25, 2022
Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort studyJohn M Dennis, Katherine G Young, Andrew P McGovern, et al.
Communications Medicine|October 4, 2023
Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic reviewKatherine G Young, Eram Haider McInnes, Robert J Massey, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 4, 2017
Measuring Success in Global Health Training: Data From 14 Years of a Postdoctoral Fellowship in Infectious Diseases and Tropical MedicineJoseph D Tucker, Molly A Hughes, Ravi V Durvasula, et al.
The American Journal of Gastroenterology|December 12, 2012
Relationship between proximal Crohn's disease location and disease behavior and surgery: a cross-sectional study of the IBD Genetics ConsortiumMark Lazarev, Chengrui Huang, Alain Bitton, et al.
Pageof 38

Showing results (321-330 of 376) with videos related to

Sort By:
Pageof 38
The Lancet. Primary Care|May 11, 2026
Kidney outcomes with GLP-1 receptor agonists in people with type 2 diabetes already receiving SGLT2 inhibitors: a target trial emulation study using UK primary care dataThijs T Jansz, Andrew P McGovern, Katherine G Young, et al.
The American Journal of Sports Medicine|September 30, 2022
Relationship of Average Outcomes Scores and Change in Status Requires Further Interpretation Between 1 and 2 Years Following Hip ArthroscopyRyan P McGovern, RobRoy L Martin, John J Christoforetti, et al.
Diabetes, Obesity & Metabolism|June 4, 2026
Trends in Second-Line Initiations and Treatment Outcomes Across Age and Frailty Groups in People With Type 2 Diabetes: UK Population-Based Study, 2019-2024M M Dinsdale, K G Young, P Cardoso, et al.
Lancet (London, England)|February 28, 2025
A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation studyJohn M Dennis, Katherine G Young, Pedro Cardoso, et al.
Diabetes Care|May 20, 2026
Precision Prescribing of SGLT2 Inhibitors in Individuals With Type 2 Diabetes for Primary Prevention of Heart Failure: Model Development and Validation StudyKatherine G Young, Andrew P McGovern, Rhian Hopkins, et al.
Medrxiv : the Preprint Server for Health Sciences|May 3, 2023
Precision medicine in type 2 diabetes: A systematic review of treatment effect heterogeneity for GLP1-receptor agonists and SGLT2-inhibitorsKatherine G Young, Eram Haider McInnes, Robert J Massey, et al.
The Lancet. Digital Health|November 25, 2022
Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort studyJohn M Dennis, Katherine G Young, Andrew P McGovern, et al.
Communications Medicine|October 4, 2023
Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic reviewKatherine G Young, Eram Haider McInnes, Robert J Massey, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 4, 2017
Measuring Success in Global Health Training: Data From 14 Years of a Postdoctoral Fellowship in Infectious Diseases and Tropical MedicineJoseph D Tucker, Molly A Hughes, Ravi V Durvasula, et al.
The American Journal of Gastroenterology|December 12, 2012
Relationship between proximal Crohn's disease location and disease behavior and surgery: a cross-sectional study of the IBD Genetics ConsortiumMark Lazarev, Chengrui Huang, Alain Bitton, et al.
Pageof 38